163 related articles for article (PubMed ID: 35815190)
1. Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.
Mcbreairty BE; Chobrutskiy BI; Chobrutskiy A; Gozlan EC; Diaz MJ; Blanck G
Biomed Rep; 2022 Aug; 17(2):68. PubMed ID: 35815190
[TBL] [Abstract][Full Text] [Related]
2. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
[TBL] [Abstract][Full Text] [Related]
3. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
4. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
[TBL] [Abstract][Full Text] [Related]
5. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
[TBL] [Abstract][Full Text] [Related]
6. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
[TBL] [Abstract][Full Text] [Related]
7. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
[TBL] [Abstract][Full Text] [Related]
8. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract][Full Text] [Related]
9. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
[TBL] [Abstract][Full Text] [Related]
10. Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells.
Gozlan EC; Chobrutskiy BI; Zaman S; Yeagley M; Blanck G
J Mol Neurosci; 2021 Nov; 71(11):2393-2404. PubMed ID: 33666857
[TBL] [Abstract][Full Text] [Related]
11. A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma.
Patel DN; Yeagley M; Arturo JF; Falasiri S; Chobrutskiy BI; Gozlan EC; Blanck G
Int J Immunogenet; 2021 Oct; 48(5):409-418. PubMed ID: 34298587
[TBL] [Abstract][Full Text] [Related]
12. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
[TBL] [Abstract][Full Text] [Related]
13. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
Agnila DRL; Huda TI; Eakins RA; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Melanoma Res; 2023 Aug; 33(4):275-282. PubMed ID: 37222076
[TBL] [Abstract][Full Text] [Related]
14. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
[TBL] [Abstract][Full Text] [Related]
15. Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.
Cios KJ; Huda TI; Eakins RA; Mihyu MM; Blanck G
Leuk Lymphoma; 2022 Jun; 63(6):1314-1322. PubMed ID: 35019822
[TBL] [Abstract][Full Text] [Related]
16. IGH Complementarity Determining Region-3-Cytomegalovirus Protein Chemical Complementarity Linked to Better Overall Survival Probabilities for Glioblastoma.
Hudock TR; Song JJ; Chobrutskiy A; Chobrutskiy BI; Blanck G
Viral Immunol; 2024 Jun; ():. PubMed ID: 38848306
[TBL] [Abstract][Full Text] [Related]
17. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.
Diaz MJ; Chobrutskiy BI; Zaman S; Blanck G
Cancer Treat Res Commun; 2020; 24():100196. PubMed ID: 32769037
[TBL] [Abstract][Full Text] [Related]
18. Exploiting adaptive immune receptor recombination read recoveries from exome files to identify subsets of ALL and to establish TCR features that correlate with better outcomes.
Gozlan EC; Chobrutskiy BI; Blanck G
Int J Lab Hematol; 2022 Oct; 44(5):883-891. PubMed ID: 35527672
[TBL] [Abstract][Full Text] [Related]
19. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer.
Chobrutskiy BI; Zaman S; Diviney A; Mihyu MM; Blanck G
J Cancer Res Clin Oncol; 2019 Mar; 145(3):615-623. PubMed ID: 30539280
[TBL] [Abstract][Full Text] [Related]
20. Immunogenomics Parameters for Patient Stratification in Alzheimer's Disease.
Huda TI; Diaz MJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Alzheimers Dis; 2022; 88(2):619-629. PubMed ID: 35662120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
